These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 8473644)

  • 61. Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans.
    Fiorucci S; Mencarelli A; Meneguzzi A; Lechi A; Renga B; del Soldato P; Morelli A; Minuz P
    J Am Coll Cardiol; 2004 Aug; 44(3):635-41. PubMed ID: 15358033
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics.
    Kumlin M; Dahlén B; Björck T; Zetterström O; Granström E; Dahlén SE
    Am Rev Respir Dis; 1992 Jul; 146(1):96-103. PubMed ID: 1320824
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evidence for episodic platelet activation in acute ischemic stroke.
    van Kooten F; Ciabattoni G; Patrono C; Schmitz PI; van Gijn J; Koudstaal PJ
    Stroke; 1994 Feb; 25(2):278-81. PubMed ID: 8303731
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation.
    Petrucci G; Zaccardi F; Giaretta A; Cavalca V; Capristo E; Cardillo C; Pitocco D; Porro B; Schinzari F; Toffolo G; Tremoli E; Rocca B
    J Thromb Haemost; 2019 Jun; 17(6):885-895. PubMed ID: 30933424
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Absence of differential inhibition of thromboxane A2 and prostacyclin by low and high dose aspirin in coronary artery disease.
    Klein RC; Beckman J; Peake G
    Can J Cardiol; 1987 Sep; 3(6):288-92. PubMed ID: 3322532
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus.
    Ferro D; Basili S; Roccaforte S; Di Franco M; Cipollone F; Ciabattoni G; Davì G
    Arthritis Rheum; 1999 Dec; 42(12):2689-97. PubMed ID: 10616019
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Post interventional cardiology urinary thromboxane correlates with PlateletMapping detected aspirin resistance.
    Carroll RC; Worthington RE; Craft RM; Snider CC; Dakin PA; Wortham DC; Scott J; Jarrett A
    Thromb Res; 2010 Apr; 125(4):e118-22. PubMed ID: 19962724
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ridogrel in the setting of percutaneous transluminal coronary angioplasty.
    Timmermans C; Vrolix M; Vanhaecke J; Stammen F; Piessens J; Vercammen E; De Geest H
    Am J Cardiol; 1991 Aug; 68(5):463-6. PubMed ID: 1872272
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Thromboxane biosynthesis and future events in diabetes: the ASCEND trial.
    Petrucci G; Buck GA; Rocca B; Parish S; Baigent C; Hatem D; Mafham M; Habib A; Bowman L; Armitage J; Patrono C
    Eur Heart J; 2024 Apr; 45(15):1355-1367. PubMed ID: 38385506
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
    Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
    Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
    Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
    Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Fractional conversion of thromboxane A2 and B2 to urinary 2,3-dinor-thromboxane B2 and 11-dehydrothromboxane B2 in the cynomolgus monkey.
    Patrignani P; Morton H; Cirino M; Lord A; Charette L; Gillard J; Rokach J; Patrono C
    Biochim Biophys Acta; 1989 Jul; 992(1):71-7. PubMed ID: 2752041
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of effects of low-dose aspirin administration on urinary thromboxane metabolites in healthy dogs.
    Hoh CM; Smith SA; McMichael MA; Byron JK
    Am J Vet Res; 2011 Aug; 72(8):1038-45. PubMed ID: 21801060
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus.
    Falco A; Salvati F; Vitacolonna E; Avellone G; Pinto A; Di Febbo C; Ballone E; Di Nicola M; Ciabattoni G; Davì G
    Atherosclerosis; 2005 Dec; 183(2):329-35. PubMed ID: 16285996
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
    Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
    Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy.
    Dragani A; Pascale S; Recchiuti A; Mattoscio D; Lattanzio S; Petrucci G; Mucci L; Ferrante E; Habib A; Ranelletti FO; Ciabattoni G; Davì G; Patrono C; Rocca B
    Blood; 2010 Feb; 115(5):1054-61. PubMed ID: 19887674
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Aspirin Resistance in Different Doses by Bleeding Time and Urinary 11-dehydro-thromboxane B2.
    Maleki A; Cheraghi M; Kerman SRJ; Montazeri M; Rashidi N; Ghanavati R; Foroughi S; Alyari F; Ahmadvand H
    Indian J Physiol Pharmacol; 2016; 60(1):30-7. PubMed ID: 29953191
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The change of urinary 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin F1 alpha in arteriogenic impotence.
    Lin JS; Lui SM; Chen CM; Chang WC
    J Urol; 1992 Aug; 148(2 Pt 1):311-3. PubMed ID: 1635125
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes.
    Cerletti C; Dell'Elba G; Manarini S; Pecce R; Di Castelnuovo A; Scorpiglione N; Feliziani V; de Gaetano G
    Clin Pharmacokinet; 2003; 42(12):1059-70. PubMed ID: 12959636
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis.
    Yang M; Ye Z; Mei L; Ullah I; Tan C; Wang G; Gu Q; Lu Y; Abdus S; Shi L; Gong X; Bai J; Eikelboom JW; Li C
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1815-1823. PubMed ID: 34331551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.